Galectin Therapeutics (GALT) shares have fallen sharply after the company announced that it will cease development of NASH candidate GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis after a small open-label Phase 2a study failed to demonstrate at least a 75% improvement in symptoms after 24 weeks of treatment. Results for four patients showed an improvement in PASI scores of 27 - 60% after 13 doses (8 mg/kg infusions every other week).